Thrivent Financial For Lutherans Ligand Pharmaceuticals Inc Transaction History

Thrivent Financial For Lutherans

  • $52.6 Billion
  • Q3 2024

A detailed history of Thrivent Financial For Lutherans transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 15,084 shares of LGND stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,084
Previous 14,755 2.23%
Holding current value
$1.8 Million
Previous $1.24 Million 21.48%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024
BUY
$82.7 - $110.11 $27,208 - $36,226
329 Added 2.23%
15,084 $1.51 Million
Q2 2024

Aug 13, 2024
SELL
$68.53 - $87.91 $16,652 - $21,362
-243 Reduced 1.62%
14,755 $1.24 Million
Q1 2024

May 14, 2024
SELL
$68.64 - $89.2 $26,495 - $34,431
-386 Reduced 2.51%
14,998 $1.1 Million
Q4 2023

Feb 14, 2024
SELL
$49.57 - $72.63 $17,795 - $26,074
-359 Reduced 2.28%
15,384 $1.1 Million
Q3 2023

Nov 14, 2023
SELL
$58.86 - $72.67 $45,557 - $56,246
-774 Reduced 4.69%
15,743 $943,000
Q2 2023

Aug 14, 2023
SELL
$69.53 - $79.33 $18,703 - $21,339
-269 Reduced 1.6%
16,517 $1.19 Million
Q1 2023

May 17, 2023
BUY
$65.67 - $77.08 $21,211 - $24,896
323 Added 1.96%
16,786 $1.24 Million
Q4 2022

Feb 08, 2023
SELL
$61.72 - $96.74 $7,221 - $11,318
-117 Reduced 0.71%
16,463 $1.1 Million
Q3 2022

Nov 14, 2022
BUY
$0.01 - $107.56 $0 - $1,505
14 Added 0.08%
16,580 $1.43 Million
Q2 2022

Aug 16, 2022
BUY
$74.52 - $117.06 $220,653 - $346,614
2,961 Added 21.76%
16,566 $1.48 Million
Q1 2022

May 13, 2022
BUY
$94.99 - $151.56 $474 - $757
5 Added 0.04%
13,605 $1.53 Million
Q4 2021

Feb 16, 2022
BUY
$127.69 - $165.85 $15,322 - $19,902
120 Added 0.89%
13,600 $2.1 Million
Q3 2021

Nov 15, 2021
BUY
$102.33 - $144.73 $927,007 - $1.31 Million
9,059 Added 204.91%
13,480 $1.88 Million
Q2 2021

Aug 19, 2021
BUY
$113.03 - $155.64 $565 - $778
5 Added 0.11%
4,421 $580,000
Q1 2021

May 17, 2021
SELL
$99.52 - $215.83 $5.46 Million - $11.8 Million
-54,865 Reduced 92.55%
4,416 $673,000
Q4 2020

Feb 16, 2021
BUY
$80.55 - $106.05 $35,361 - $46,555
439 Added 0.75%
59,281 $5.9 Million
Q3 2020

Nov 10, 2020
SELL
$89.56 - $126.72 $147,953 - $209,341
-1,652 Reduced 2.73%
58,842 $5.61 Million
Q2 2020

Aug 12, 2020
SELL
$68.28 - $123.65 $3.35 Million - $6.07 Million
-49,123 Reduced 44.81%
60,494 $6.77 Million
Q1 2020

May 15, 2020
SELL
$63.37 - $107.88 $26.5 Million - $45.2 Million
-418,855 Reduced 79.26%
109,617 $7.97 Million
Q4 2019

Feb 13, 2020
BUY
$96.94 - $113.59 $7.86 Million - $9.21 Million
81,109 Added 18.13%
528,472 $55.1 Million
Q3 2019

Nov 14, 2019
BUY
$86.25 - $120.16 $1.18 Million - $1.65 Million
13,729 Added 3.17%
447,363 $44.5 Million
Q2 2019

Aug 13, 2019
BUY
$107.38 - $129.34 $742,317 - $894,127
6,913 Added 1.62%
433,634 $49.5 Million
Q1 2019

May 14, 2019
BUY
$105.93 - $142.47 $15.6 Million - $21 Million
147,537 Added 52.85%
426,721 $53.6 Million
Q4 2018

Feb 15, 2019
BUY
$128.36 - $272.13 $34 Million - $72.1 Million
264,797 Added 1840.53%
279,184 $37.9 Million
Q3 2018

Nov 15, 2018
SELL
$211.18 - $274.49 $50,472 - $65,603
-239 Reduced 1.63%
14,387 $3.95 Million
Q2 2018

Aug 14, 2018
BUY
$150.77 - $207.98 $62,268 - $85,895
413 Added 2.91%
14,626 $3.03 Million
Q1 2018

May 08, 2018
BUY
$138.63 - $182.62 $154,572 - $203,621
1,115 Added 8.51%
14,213 $2.35 Million
Q4 2017

Feb 14, 2018
BUY
$128.36 - $147.04 $33,116 - $37,936
258 Added 2.01%
13,098 $1.79 Million
Q3 2017

Nov 14, 2017
BUY
$120.91 - $137.94 $1.55 Million - $1.77 Million
12,840
12,840 $1.75 Million

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2.01B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email